Berenberg and Goldman Sachs Second German Corporate Conference. Company Update September 24, 2013
|
|
- Juniper Greene
- 5 years ago
- Views:
Transcription
1 Berenberg and Goldman Sachs Second German Corporate Conference Company Update September 24, 2013
2 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations and the availability of financing. These and other risks and uncertainties are detailed in the Company s Annual Report. 2
3 Highlights Two Major Alliances for Proprietary Antibodies Alliance with Celgene for co-development & co-promotion of MOR202 Successful out-licensing of MOR103 to GSK Pipeline Progress 21 programs in clinical development Strong Financial Performance Recurring cash-flows Sale of AbD, GSK & Celgene deals 3
4 Innovative Product Pipeline 4
5 The MorphoSys Pipeline 21 Clinical Programs, 81 Total Program Partner Target Indication Discovery Preclinic Phase 1 Phase 2 Phase 3 Gantenerumab Roche Amyloid-ß Alzheimer s Disease MOR103 (2 programs) Guselkumab (CNTO1959) (2 programs) GSK Janssen/J&J GM-CSF IL23p19 BHQ880 Novartis DKK-1 Cancer Rheumatoid Arthritis Multiple Sclerosis Psoriasis Rheumatoid Arthritis Bimagrumab (BYM338) Novartis ActRIIB Musculoskeletal NOV 3 Novartis - not discl. LFG316 Novartis C5 Ophthalmology OMP-59R5 OncoMed/GSK Notch 2 Cancer CNTO3157 Janssen/J&J - Asthma CNTO6785 Janssen/J&J - Rheumatoid Arthritis MOR208 - CD19 CLL, NHL, ALL MOR202 Celgene/MOR CD38 Multiple Myeloma BAY Bayer Healthcare Mesothelin (ADC) Cancer BI 1 BI - not discl. VAY736 Novartis BAFF-R Inflammation LJM716 Novartis HER3 Cancer Vantictumab (OMP-18R5) OncoMed/Bayer Fzd 7 Cancer PFE 1 Pfizer - Cancer NOV - 7 Novartis - Ophthalmology 22 Programs Various Partners - Various Indications 38 Programs Various Partners 3 Proprietary Pr. - Various Indications 74 Partnered Programs 7 MOR Programs 5
6 HuCAL: The Most Successful Antibody Library Technology in the Industry HuCAL Human Combinatorial Antibody Library Modular gene structure enables systematic creation of drug quality antibodies 20 40% HuCAL programs in clinic Success rate from target to IND Most successful antibody library Transforming R&D productivity 6
7 MOR202 A Novel Antibody for Multiple Myeloma Large Market and Unmet Need Revenues with approved drugs in MM exceed $2bn Responders eventually relapse or become refractory to existing therapies MOR202 High affinity HuCAL antibody targeting CD38 Competitive Profile Preclinical data show strong synergy in combinations of MOR202 with Velcade or Revlimid Clinical Development Phase 1/2a clinical trial in relapsed or refractory MM patients currently ongoing Strategic Alliance with Celgene Joint development of MOR202 globally and co-promotion in Europe 7
8 Alliance with Celgene for MOR202 Scope Global co-development and European co-promotion agreement Costs: 1/3 MorphoSys, 2/3 Celgene Up-front MOR receives EUR 70.8 million Equity Celgene pays EUR 46.2 million for 3.4% stake in MOR at EUR per share 53% premium to pre-announcement price Milestones Up to EUR 511 million in development, regulatory and sales milestones Commercialization Co-promotion in Europe with 50:50 profit share Exclusive Celgene in rest-of-world, tiered double digit royalties to MOR 8
9 MOR103 Global License Agreement with GSK MOR103 Ultra-high affinity HuCAL IgG1 targeting GM-CSF Potential for superior efficacy and better safety than current treatments Phase 1b/2a trial in RA successfully completed Phase 1b in MS ongoing GSK assumes global responsibility for clinical development and commercialization of MOR103 in all indications MorphoSys receives EUR 22.5 million upfront payment Up to EUR 423 million in success-based payments Tiered, double-digit royalties on net sales 9
10 % of patients Mean change from baseline MOR103 Compelling Clinical Data ACR20* DAS MOR mg/kg mavrilimumab Humira Orencia Actemra Week Time (weeks) Very fast onset of therapeutic effect Durable response Clean safety profile Administration of MOR103 * Data from separate clinical studies 10
11 MOR208 (XmAb5574) A Novel Anti-Cancer Antibody Large Market and Unmet Need Large unmet medical need in NHL, CLL & ALL Revenues with approved drugs for B cell malignancies exceed $5bn MOR208 Anti-CD19 antibody in-licensed from Xencor CD19 expressed earlier than CD20 potential greater efficacy vs. anti-cd20s Proprietary modification in Fc region increased ADCC rapid & sustained B-cell depletion Minor modification means convenient dosing schedule, straightforward manufacturing Blinatumomab data validate CD19 as target for B-cell malignancies 11
12 MOR208 Phase 1/2a Trial in CLL/SLL Trial Design Phase 1, multi-center, US study in heavily pre-treated, relapsed or refractory CLL/SLL patients Dosage 0.3 mg/kg - 12 mg/kg; days 1&4, weeks 2-8 Results Acceptable safety profile Responses observed in 67% of patients by physical exam 4/27 (15%) partial responses and 20/27 (74%) patients with stable disease (IWCLL 2008 criteria including CT) Full results from trial extension expected in Q Phase 2 Phase 2 trials in ALL and NHL ongoing Combination therapy study in CLL being considered 12
13 The MorphoSys Pipeline 21 Clinical Programs, 81 Total Program Partner Target Indication Discovery Preclinic Phase 1 Phase 2 Phase 3 Gantenerumab Roche Amyloid-ß Alzheimer s Disease MOR103 (2 programs) Guselkumab (CNTO1959) (2 programs) GSK Janssen/J&J GM-CSF IL23p19 BHQ880 Novartis DKK-1 Cancer Rheumatoid Arthritis Multiple Sclerosis Psoriasis Rheumatoid Arthritis Bimagrumab (BYM338) Novartis ActRIIB Musculoskeletal NOV 3 Novartis - not discl. LFG316 Novartis C5 Ophthalmology OMP-59R5 OncoMed/GSK Notch 2 Cancer CNTO3157 Janssen/J&J - Asthma CNTO6785 Janssen/J&J - Rheumatoid Arthritis MOR208 - CD19 CLL, NHL, ALL MOR202 Celgene/MOR CD38 Multiple Myeloma BAY Bayer Healthcare Mesothelin (ADC) Cancer BI 1 BI - not discl. VAY736 Novartis BAFF-R Inflammation LJM716 Novartis HER3 Cancer Vantictumab (OMP-18R5) OncoMed/Bayer Fzd 7 Cancer PFE 1 Pfizer - Cancer NOV - 7 Novartis - Ophthalmology 22 Programs Various Partners - Various Indications 38 Programs Various Partners 3 Proprietary Pr. - Various Indications 74 Partnered Programs 7 MOR Programs 13
14 Gantenerumab: A HuCAL Antibody Being Developed by Roche for Alzheimer s Disease Large Market and Unmet Need Alzheimer s disease is estimated to affect 25 million people worldwide Increasing with aging population Once symptoms for AD dementia have appeared, it may be too late to treat Picture: Courtesy of Roche 14
15 % Amyloid change from baseline Gantenerumab: The Most Advanced Antibody in Development for Alzheimer s Disease Gantenerumab High affinity HuCAL antibody targeting amyloid-β Binds & breaks down amyloid-β fibrils and plaques Clinical Development Phase 1: gantenerumab reduces brain amyloid 3x faster than other amyloid-targeting substances Phase 3 study (Roche) 770 prodromal patients, 2 doses (105mg & 225mg s.c.), placebo-controlled 104 weeks on drug, with an option for an additional 2 years of treatment Primary Endpoint: Change in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) Data expected 2016 Phase 3 study (Dominantly Inherited Alzheimer Network) Genetically pre-disposed subjects Data from Phase 1 Effect of gantenerumab on amyloid load as indexed by PET SUVR at end of treatment Data: Courtesy of Roche 15
16 The MorphoSys Pipeline 21 Clinical Programs, 81 Total Program Partner Target Indication Discovery Preclinic Phase 1 Phase 2 Phase 3 Gantenerumab Roche Amyloid-ß Alzheimer s Disease MOR103 (2 programs) Guselkumab (CNTO1959) (2 programs) GSK Janssen/J&J GM-CSF IL23p19 BHQ880 Novartis DKK-1 Cancer Rheumatoid Arthritis Multiple Sclerosis Psoriasis Rheumatoid Arthritis Bimagrumab (BYM338) Novartis ActRIIB Musculoskeletal NOV 3 Novartis - not discl. LFG316 Novartis C5 Ophthalmology OMP-59R5 OncoMed/GSK Notch 2 Cancer CNTO3157 Janssen/J&J - Asthma CNTO6785 Janssen/J&J - Rheumatoid Arthritis MOR208 - CD19 CLL, NHL, ALL MOR202 Celgene/MOR CD38 Multiple Myeloma BAY Bayer Healthcare Mesothelin (ADC) Cancer BI 1 BI - not discl. VAY736 Novartis BAFF-R Inflammation LJM716 Novartis HER3 Cancer Vantictumab (OMP-18R5) OncoMed/Bayer Fzd 7 Cancer PFE 1 Pfizer - Cancer NOV - 7 Novartis - Ophthalmology 22 Programs Various Partners - Various Indications 38 Programs Various Partners 3 Proprietary Pr. - Various Indications 74 Partnered Programs 7 MOR Programs 16
17 Bimagrumab (BYM338) A Novartis Musculoskeletal Program Bimagrumab is a HuCAL antibody against ActRIIB Novartis received FDA breakthrough therapy designation for sporadic inclusion body myositis (sibm) Phase 2 study showed that bimagrumab substantially benefited patients with sibm Results will be presented at the American Neurological Association meeting on Oct. 14, 2013 In Phase 2 development for Sporadic inclusion body myositis Cancer-related cachexia COPD-related cachexia Sarcopenia Mechanically ventilated patients Recently Highlighted by Novartis Imagine the equivalent of 8 or 10 weeks of exercise in one injection Listed as a planned filing 2016 Source: 17
18 The MorphoSys Pipeline 21 Clinical Programs, 81 Total Program Partner Target Indication Discovery Preclinic Phase 1 Phase 2 Phase 3 Gantenerumab Roche Amyloid-ß Alzheimer s Disease MOR103 (2 programs) Guselkumab (CNTO1959) (2 programs) GSK Janssen/J&J GM-CSF IL23p19 BHQ880 Novartis DKK-1 Cancer Rheumatoid Arthritis Multiple Sclerosis Psoriasis Rheumatoid Arthritis Bimagrumab (BYM338) Novartis ActRIIB Musculoskeletal NOV 3 Novartis - not discl. LFG316 Novartis C5 Ophthalmology OMP-59R5 OncoMed/GSK Notch 2 Cancer CNTO3157 Janssen/J&J - Asthma CNTO6785 Janssen/J&J - Rheumatoid Arthritis MOR208 - CD19 CLL, NHL, ALL MOR202 Celgene/MOR CD38 Multiple Myeloma BAY Bayer Healthcare Mesothelin (ADC) Cancer BI 1 BI - not discl. VAY736 Novartis BAFF-R Inflammation LJM716 Novartis HER3 Cancer Vantictumab (OMP-18R5) OncoMed/Bayer Fzd 7 Cancer PFE 1 Pfizer - Cancer NOV - 7 Novartis - Ophthalmology 22 Programs Various Partners - Various Indications 38 Programs Various Partners 3 Proprietary Pr. - Various Indications 74 Partnered Programs 7 MOR Programs 18
19 Guselkumab A Janssen Anti-Inflammatory Program Guselkumab is a HuCAL antibody against IL-23 Phase 2 development for psoriasis Phase 2 study vs. Stelara in rheumatoid arthritis Specific for IL-23 Guselkumab binds the p19 sub-unit of IL-23, while Stelara binds the p40 sub-unit of IL-23 and IL-12 Highlighted at Janssen s Last Analyst Day Listed under planned filings Sources: Jetten AM, Nucl Recept Signal,
20 Technology 20
21 New Technologies Enabling the Creation of Differentiated Drugs Differentiated Drug Candidates Ylanthia Totally new antibody platform Higher quality antibodies, greater diversity faster access to superior drug leads US patent granted January 2013 Lantipeptides Alliance with Lanthio Pharma to develop lantipeptide libraries for drug discovery Preferred rights to exclusive license MorphoSys has minority equity position New Target Classes Antibodies Against GPCRs MorphoSys secures access to stabilized GPCRs produced by Heptares MorphoSys will make and offer antibodies against GPCRs Most important target class; challenging for antibodies 21
22 Strong Financials 22
23 Shareholdings Shareholdings by Investor Type Institutional Investors - 52% Novartis - 6% Celgene - 3% Treasury Stock - 2% Management & Supervisory Boards - 2% Retail Investors - 20% Unidentified Investors - 15% Geographic Split of Institutional Holdings USA: 58% Scandinavia: 12% United Kingdom: 10% Switzerland: 7% Benelux: 6% Germany: 5% 15% 20% 52% 2% 2% 3% 6% MorphoSys AG (FSE: MOR, Prime Standard, TecDAX; OTC: MPSYY) Shares issued: 24,591,443 (August 31, 2013) 23
24 Key Financials in EUR million H Guidance 2013* Group Revenues EBIT to 6 Cash & Marketable Securities and Interest-bearing Assignable Loans as of June 30, ** * Updated following MOR202 regulatory clearance (August 10, 2013) ** Cash position does not include any payments from GSK or Celgene, nor the proceeds from the capital increase placed in September 24
25 Outstanding Recent Progress MOR202 Co-development partnership with Celgene MOR103 Partnership with GSK MOR208 Promising Phase 1 data in CLL Phase 2 studies in ALL and NHL started Bimagrumab Breakthrough therapy designation NOV-7 Seventh program enters clinic from Novartis alliance
26 Clinical Trials Scheduled for Completion Partnered Phase 2 Phase 1 Bimagrumab Cachexia (cancer) Bimagrumab Sarcopenia Guselkumab Palmoplantar Postulosis Guselkumab RA (vs. Stelara) Bimagrumab Ventilated Patients Proprietary Phase 2 Phase 1 LFG316 AMD LFG316 MCP Guselkumab Psoriasis LFG316 NOV-3 Wet AMD undisclosed Bimagrumab Cachexia (COPD) NOV-3 Undisclosed BHQ880 MM/Renal Insufficiency NOV-3 undisclosed MOR103 Multiple sclerosis MOR208 B-ALL BHQ880 Smoldering MM MOR208 CLL (extension arm) BI-1 undisclosed BI-1 undisclosed BAY (ADC) Solid Tumors Gantenerumab Liquid vs. Lyophilized Guselkumab Devices/Formulation Gantenerumab AD/Japan CNTO3157 Asthma Guselkumab Psoriasis (Japan) OMP-59R5 Solid Tumors OMP-18R5 Solid Tumors LJM716 Single LJM716 Combo 2013 Potential data events based on clinical trial design & MorphoSys estimates
27 Thank You Dr. Claudia Gutjahr-Löser Head of Corporate Communications & IR Phone +49 (0)89 / Fax +49 (0)89 / investors@morphosys.com HuCAL, HuCAL GOLD, HuCAL PLATINUM, CysDisplay, RapMAT, aryla, Ylanthia and 100 billion high potentials are registered trademarks of MorphoSys AG. Slonomics is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.
Bank of America Merrill Lynch Global Healthcare Conference. Company Update London, September 18, 2014
Bank of America Merrill Lynch Global Healthcare Conference Company Update London, September 18, 2014 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially
More informationJefferies 2015 Healthcare Conference. Company Update. June 3, 2015
Jefferies 2015 Healthcare Conference Company Update June 3, 2015 MorphoSys - June 2015 1 Safe Harbor This presentation includes forward-looking statements. Actual results could differ materially from those
More informationLEERINK Partners Emerging Biotech Conference March Company Update Arndt Schottelius, MD, PhD Chief Development Officer
LEERINK Partners Emerging Biotech Conference March 2016 Company Update Arndt Schottelius, MD, PhD Chief Development Officer Safe Harbor This presentation includes forward-looking statements. Actual results
More informationDeutsche Bank 41st Annual Health Care Conference. Company Update May 5, 2016
Deutsche Bank 41st Annual Health Care Conference Company Update May 5, 2016 Safe Harbor This presentation includes forward-looking statements. Actual results could differ materially from those included
More informationInvestor Reception ASCO June 6, 2016
Investor Reception ASCO 216 June 6, 216 MorphoSys - ASCO - June 6, 216 1 Safe Harbor This presentation includes forward-looking statements. Actual results could differ materially from those included in
More informationEngineering the Medicines of Tomorrow
APRIL 2017 Engineering the Medicines of Tomorrow Company Update This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking
More informationEngineering the Medicines of Tomorrow
December 2018 Engineering the Medicines of Tomorrow Company Update This presentation includes forward-looking statements. This communication contains certain forward-looking statements concerning the MorphoSys
More informationIntercell and Novartis form world leading strategic partnership to drive vaccines innovation
Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell
More informationCorporate Overview. February 2018 NASDAQ: CYTR
Corporate Overview February 2018 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER
More informationDeveloping & Commercializing Targeted Small Molecule Drugs in Cancer
Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationMOLOGEN AG. Our research for you. Annual Results Analysts Call March 21, 2013
Our research for you. Annual Results 2012 Analysts Call March 21, 2013 Disclaimer Certain statements in this communication contain formulations or terms referring to the future or future developments,
More informationBuilding a Fully Integrated Biopharmaceutical Company. June 2014
Building a Fully Integrated Biopharmaceutical Company June 2014 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation
More informationAnti-IL-33 (ANB020) Program
Anti-IL-33 (ANB020) Program Phase 2a Peanut Allergy Clinical Trial Interim Data Update March 26 th 2018 NASDAQ: ANAB Safe Harbor Statement This presentation and the accompanying oral presentation contain
More informationCorporate Presentation
Corporate Presentation March 2018 Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward-looking" statements within the meaning of the United States Private Securities
More informationBioCryst Pharmaceuticals
BioCryst Pharmaceuticals Jefferies 2010 Global Life Sciences Conference New York Stuart Grant Senior Vice President & Chief Financial Officer Rob Bennett Executive Director, Investor Relations & Business
More informationNASDAQ: CYTR FIGHTING CANCER WITH CUTTING EDGE SCIENCE. Corporate Overview. July 2018
NASDAQ: CYTR Corporate Overview July 2018 CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationSunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results
Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717 Sunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results SOUTH
More informationIdenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston
Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Safe Harbor This presentation includes forward-looking statements
More informationSumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company)
December 21, 2016 Sumitomo Dainippon Pharma Co., Ltd. Sumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company) Sumitomo Dainippon Pharma Co., Ltd. (Head office: Osaka,
More informationInvestor Presentation
Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities
More informationMemory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia. -Broadens Roche Nicotinic Alpha-7 Alliance-
Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia -Broadens Roche Nicotinic Alpha-7 Alliance- -Secures Additional $5M Debt Financing to Support Phase 2a Trial-
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationTELECONFERENCE FY February 2015
TELECONFERENCE FY 2014 5 February 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationImmuno-Oncology: Cancer Therapies Powered by the Immune System
European Business Development Conference Dresden - October 7/8, 2014 Immuno-Oncology: Cancer Therapies Powered by the Immune System Dr. Marlies Sproll, CSO Power of the Immune System Vaccination as Success
More informationLeading R&D pipeline with proven technology. Partners. Injection and drop-based allergy immunotherapy products
ALK at a glance The leading allergy immunotherapy specialist 33% of global allergy immunotherapy market Leading R&D pipeline with proven technology Strategic partnerships to globalise SLIT- tablet portfolio
More informationH. LUNDBECK A/S. Teleconference. 10 August PM CET. Financial results Second quarter 2011
H. LUNDBECK A/S Teleconference 10 August 2011-2PM CET Financial results Second quarter 2011 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts
More informationMOLOGEN AG. Our research for you. German Equity Forum November 2012
Our research for you. German Equity Forum 12-14 November 2012 Disclaimer Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More information9M RESULTS 2014 CONFERENCE CALL DR. MATTHIAS SCHROFF, CEO
9M RESULTS 2014 CONFERENCE CALL DR. MATTHIAS SCHROFF, CEO BERLIN, 13 NOVEMBER, 2014 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments,
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,
More informationDynavax Corporate Presentation
Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,
More informationSpecial Meeting in Lieu of Annual Meeting of Shareholders
Special Meeting in Lieu of Annual Meeting of Shareholders Thursday, June 19, 2008 James A. Bianco, M.D. President and CEO Agenda Call meeting to order Introduction of the inspector of elections, secretary,
More informationCorporate Overview May 8, 2014
0 Corporate Overview May 8, 2014 NASDAQ: CRIS Forward Looking Statements This presentation contains statements about Curis future expectations, plans and prospects that constitute forward-looking statements
More informationCAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month
More informationCorporate Presentation Asia Investment Series March 2018
Corporate Presentation Asia Investment Series March 2018 Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward-looking" statements within the meaning of the United
More informationPutting ALK on the right growth trajectory
Putting ALK on the right growth trajectory Økonomisk Ugebrevs Kapitalmarkedseftermiddag 15. marts 2018 Per Plotnikof, VP Corporate Communications and IR Marts 2018 Allergy: a global disease with a large
More informationPSMA-617 License Transaction. October 2, 2017
PSMA-617 License Transaction October 2, 2017 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending,
More informationCAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month
More informationCompany update. March 2012
Company update March 2012 Oncology-focused biopharmaceutical company Product candidates with strong competitive profiles Integrative approach through combination of therapeutics and diagnostics Transition
More informationJefferies 2015 Healthcare Conference
Jefferies 2015 Healthcare Conference Paul J. Hastings Chairman and Chief Executive Officer June 2, 2015 Safe Harbor Statement These slides and accompanying oral presentation contain forward-looking statements.
More informationValneva Reports Strong 2017 Revenues Driven by Double Digit Product Sales Growth
Valneva Reports Strong 2017 Revenues Driven by Double Digit Product Sales Growth Strong sales performance in 2017 (unaudited) Total revenues of 109.8 million in 2017 (2016-97.9 million) representing year-on-year
More informationAVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET
NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)
More informationDISCOVERING AND DEVELOPING NEW IMMUNE ACTIVATING MECHANISMS AND ANTIBODIES TO IMPROVE CANCER SURVIVAL
DISCOVERING AND DEVELOPING NEW IMMUNE ACTIVATING MECHANISMS AND ANTIBODIES TO IMPROVE CANCER SURVIVAL Annual General Meeting 24 April 2018 Björn Frendéus, Acting CEO & CSO 1 IMMUNOTHERAPY HAS TRANSFORMED
More informationCreating and developing innovative therapies. Deborah Rathjen CEO & Managing Director
Creating and developing innovative therapies Deborah Rathjen CEO & Managing Director Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward-looking" statements within
More informationTwo-stage study designed to evaluate tolerability and efficacy of pracinostat combined with azacitidine in patients with high and very high risk MDS
Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome Two-stage study designed to evaluate tolerability
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More informationJEFFERIES 2016 HEALTHCARE CONFERENCE. June 2016
JEFFERIES 2016 HEALTHCARE CONFERENCE June 2016 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationStifel Healthcare Conference John Scarlett, M.D. Chief Executive Officer November 19, 2014
Stifel Healthcare Conference 2014 John Scarlett, M.D. Chief Executive Officer November 19, 2014 1 forward-looking statements Except for statements of historical fact, the statements during this presentation
More informationMOLOGEN AG Jefferies 2014 London Healthcare Conference
Jefferies 2014 London Healthcare Conference Dr. Matthias Schroff Chief Executive Officer London 20 November 2014 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring
More informationAmicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018
Amicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018 Introduction 2 Safe Harbor This presentation contains "forward-looking statements"
More informationAstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance. Becoming Global Leaders In Diabetes
AstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance Becoming Global Leaders In Diabetes 19th December 2013 Cautionary Statement Regarding Forward-Looking Statements In order,
More informationINVESTOR PRESENTATION
INVESTOR PRESENTATION May 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities regulation.
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationJefferies Healthcare Conference. June 25, 2008
Jefferies Healthcare Conference June 25, 2008 Safe Harbor Statement Except for the historical information set forth herein, the matters set forth in this presentation,including without limitation statements
More informationEmisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results
August 11, 2008 Emisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results Conference Call/Webcast to be Held Monday, August 11 at 10:00 AM EDT CEDAR KNOLLS, N.J., Aug 11, 2008 /PRNewswire-FirstCall
More informationDecember Investor- and Analyst-Event MorphoSys AG
December 2018 Investor- and Analyst-Event MorphoSys AG Today s Speakers Dr. Simon Moroney Dr. Malte Peters Jens Holstein CEO MorphoSys AG CDO MorphoSys AG CFO MorphoSys AG 2 This presentation includes
More informationINTERIM MANAGEMENT STATEMENT Q3 2017
INTERIM MANAGEMENT STATEMENT Q3 2017 Significant progress across all clinical programs New pre-clinical immunooncology data to be presented during R&D Day in New York Research & Development highlights:
More informationIMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases November 2017 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationBayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies
More informationInvestor Presentation Post-Interim Results Update. September 2011
Investor Presentation Post-Interim Results Update September 2011 Disclaimer This presentation contains general information about the company s activities current as at 2 September 2011. It is provided
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Rodman & Renshaw 19 th Annual Global Investment Conference Michael R. Garone, Principal Executive Officer and CFO Forward-Looking
More informationBank of America Merrill Lynch 2016 Health Care Conference
Bank of America Merrill Lynch 2016 Health Care Conference Dr. Steven Stein Chief Medical Officer David Gryska Chief Financial Officer May 11, 2016 Forward Looking Statements Except for the historical information
More informationInterim report Second quarter 2017 and subsequent events (Unaudited)
SERODUS ASA Interim report Second quarter 2017 and subsequent events (Unaudited) August 2017 2017-08-15 Q2-2017 report ABOUT SERODUS Serodus is a private biotech company with a focus on diabetic comorbidities
More informationOncoMed Pharmaceuticals Jefferies Healthcare Conference. Sunil Patel, Chief Financial Officer, SVP, Corp. Development & Finance June 9, 2016
OncoMed Pharmaceuticals Jefferies Healthcare Conference Sunil Patel, Chief Financial Officer, SVP, Corp. Development & Finance June 9, 2016 Safe Harbor Statement These slides and accompanying oral presentation
More informationBuilding a Premier Oncology Biotech
Corporate Presentation Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO January 2019 Forward-Looking Statements All of the statements in this presentation that are not statements
More informationBuilding a Premier Oncology Biotech
Corporate Presentation Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO February 2019 Forward-Looking Statements All of the statements in this presentation that are not statements
More informationRoche Diagnostics Daniel O Day COO Roche Diagnostics. Société Générale - The Premium Review Conference, Paris December 2, 2011
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More informationWalgreens (WAG) Analyst: Juan Fabres Fall 2014
Recommendation: Buy Target Price August 31, 2016: $77.57 1. Reasons for the Recommendation With the acquisition of Alliance Boots in Europe, Walgreens will be the first US pharmacy to operate retail stores
More informationInvestor Event ASH 2016*
DECEMBER 5, 2016 Investor Event ASH 2016* * FOR INVESTORS ONLY. DO NOT DISSEMINATE. This presentation includes forward-looking statements. Actual results could differ materially from those included in
More informationDeborah Rathjen CEO & Managing Director 2014 Annual General Meeting
Creating and developing innovative therapies Deborah Rathjen CEO & Managing Director 2014 Annual General Meeting Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward-looking"
More informationNektar Investor & Analyst Call. Nektar & z Bristol-Myers Squibb Collaboration. February 14, 2018
Nektar Investor & Analyst Call Nektar & z Bristol-Myers Squibb Collaboration February 14, 2018 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the
More informationValue creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO
Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Coloplast has four business areas all with global sales presence Group revenue
More informationFor personal use only. General Meeting 6 March 2014
General Meeting 6 March 2014 Disclaimer Certain statements made in this presentation are forward looking statements within the meaning of the safe harbour provisions of the United States Private Securities
More informationTELECONFERENCE Q November 2015
TELECONFERENCE Q3 2015 4 November 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationMerrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference. February 7, 2007
Merrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference February 7, 2007 Information related to forward-looking statements This presentation includes forward-looking statements
More informationOur research for you. German Equity Forum November 2011
Our research for you. German Equity Forum 21-23 November 2011 Disclaimer Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as
More informationBuilding a Premier Oncology Biotech
Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical
More informationBioArctic announces positive topline results of BAN2401 Phase 2b at 18 months in early Alzheimer s Disease
Press release BioArctic announces positive topline results of BAN2401 Phase 2b at 18 months in early Alzheimer s Disease The full 18 month analysis of the 856 patient BAN2401 Phase 2b clinical study in
More informationAM-125 : Intranasal Betahistine
AM-125 : Intranasal Betahistine February 3, 2017 NASDAQ: EARS Forward-looking Statements This presentation and the accompanying oral commentary contain forward-looking statements that involve substantial
More informationPresentation to AGM 9 November Deborah Rathjen CEO & Managing Director
Presentation to AGM 9 November 2011 Deborah Rathjen CEO & Managing Director Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward looking" statements within the
More informationBayer and Regeneron start additional Phase 3 Study for VEGF Trap-Eye in Wet Age-related Macular Degeneration
Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer and Regeneron start additional Phase 3 Study for VEGF Trap-Eye in Wet Age-related Macular Degeneration International
More informationIncrease in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014
Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains
More informationArQule Jefferies Global Healthcare Conference June 2015
ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationGrowth Conference. October 19, May 2013
Dawson Corporate James Securities Presentation 3rd Annual Small Cap Growth Conference October 19, 2017 May 2013 Safe Harbor This document contains forward-looking statements within the meaning of the "safe
More informationCEO & MANAGING DIRECTOR S REPORT TO SHAREHOLDERS
ASX ANNOUNCEMENT 15 November 2017 ABN 53 075 582 740 CEO & MANAGING DIRECTOR S REPORT TO SHAREHOLDERS I am delighted to report that the past year has been a particularly strong one for the Company with
More informationJefferies 2016 Healthcare Conference. Reid Huber, PhD Chief Scientific Officer
Jefferies 2016 Healthcare Conference Reid Huber, PhD Chief Scientific Officer June 8, 2016 Forward-looking Statements Except for the historical information set forth herein, the matters set forth in this
More informationJanuary 30, 2018 Dow Wilson President and Chief Executive Officer
Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking
More informationPositioned for Growth
Positioned for Growth Annual Shareholders Meeting July 21, 2016 Paris Panayiotopoulos President and Chief Executive Officer David Sachs Non small cell lung cancer ARIAD clinical trial patient This presentation
More informationSanthera to Acquire Option from Idorsia for Exclusive Sub-License to First-in-class Dissociative Steroid Vamorolone. Webcast, 21 November 2018
Santhera to Acquire Option from Idorsia for Exclusive Sub-License to First-in-class Dissociative Steroid Vamorolone Webcast, 21 November 2018 Disclaimer This presentation is not and under no circumstances
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy NOVEMBER 2012 ERIK DAHL, CFO KATHLEEN DEARDORFF, COO Disclaimer The information included in this Presentation contains certain forward-looking statements that address
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Company presentation Per Plotnikof, VP Corporate Communications and IR 1 I ALK at a glance Commercial leader and foremost innovator within respiratory allergies
More informationCompany update German Equity Forum, Frankfurt November 2010
Company update German Equity Forum, Frankfurt November 2010 At a glance Oncology-focused biopharmaceutical company Transition from R&D to commercially driven business Product candidates close to market
More informationTargeting and Treating Cancer
Targeting and Treating Cancer Mark R. Baker, Chief Executive Officer Jefferies 2016 DISCLOSURE NOTICE This presentation may contain projections and other forward-looking statements regarding future events.
More informationLehman Brothers Eighth Annual Global Healthcare Conference March 30, 2005 Bruce A. Peacock President and Chief Executive Officer
Lehman Brothers Eighth Annual Global Healthcare Conference March 30, 2005 Bruce A. Peacock President and Chief Executive Officer 2005 Adolor Corporation. All rights reserved. Safe Harbor Statement This
More informationPresentation of ALK London, 24 May 2011 UBS GLOBAL SPECIALTY PHARMACEUTICALS CONFERENCE : LONDON : 24 MAY 2011
Presentation of ALK London, 24 May 2011 1 ALK pharma specialist - treatment, prevention and diagnosis of allergies World leader in allergy immunotherapy ~ 33% global market share Expanding Base Business
More information